8 Biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
Foundation Medicine, Inc. (FMI) gets a higher grade this week, advancing from a C last week to a B. The company also gets A’s in sales growth, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of FMI stock.
The rating of Axovant Sciences Ltd (AXON) moves up this week, rising from a C to a B. The company also gets A’s in earnings revisions and earnings surprise. For more information, get Portfolio Grader’s complete analysis of AXON stock.
Cytokinetics, Incorporated (CYTK) shows solid improvement this week. The company’s rating rises from a B to a A. Cytokinetics, Incorporated is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of CYTK stock.
ARIAD Pharmaceuticals, Inc. (ARIA) earns a B this week, jumping up from last week’s grade of C. ARIAD Pharmaceuticals, Inc. is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. The company also gets A’s in sales growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ARIA stock.
GlycoMimetics, Inc.’s (GLYC) ratings are looking better this week, moving up to a B from last week’s C. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of GLYC stock.
This is a strong week for Opexa Therapeutics, Inc. (OPXA). The company’s rating climbs to B from the previous week’s C. Opexa Therapeutics, Inc. develops cellular therapies for the treatment of multiple sclerosis, rheumatoid arthritis, pancreatic, and cardiac conditions. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of OPXA stock.
Corbus Pharmaceuticals Holdings Inc (CRBP) boosts its rating from a C to a B this week. For more information, get Portfolio Grader’s complete analysis of CRBP stock.
Immunomedics, Inc. (IMMU) is seeing ratings go up from a C last week to a B this week. Immunomedics, Inc. develops, manufactures, and sells diagnostic imaging and therapeutic products. For more information, get Portfolio Grader’s complete analysis of IMMU stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
